Share
10 April 2020 The first results of the preclinical tests of the five vaccine candidates against the SarsCoV2 virus conducted in Italy by the Takis company are positive. The company's CEO, Luigi Aurisicchio said this to Ansa."After the first experiment and with a single administration we found a strong production of antibodies. The first results in preclinical models - he added - demonstrate the strong immunogenicity of the vaccine candidates".